opioid antagonist

DRUG2 trials

Sponsors

Ikejima Kenichi, National Institute on Drug Abuse (NIDA)

Conditions

Alcohol related liver disease harm reduction, drinking markerOpioid-Related Disorders

Phase 2

Opioid Agonist and Antagonist Effects on Opioid Dependence

TerminatedNCT00142727

National Institute on Drug Abuse (NIDA)Opioid-Related Disorders

Start: 2004-01-31End: 2006-02-28Target: 16Updated: 2017-01-12

Unknown Phase

Alcohol-related liver disease and nalmefene

RecruitingJPRN-jRCT1031220022

Ikejima KenichiAlcohol related liver disease harm reduction, drinking marker

Start: 2022-04-14Target: 15Updated: 2026-06-29